🇮🇳·13h agoIndustryTier 1 · Company source
investment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limited
Publisher
N
Natco Pharma
India
This page provides publisher metadata, and related coverage to support discovery before sending readers to the publisher's original article.
Read originalAt a glance
- Publisher
- Natco Pharma
- Region
- India
- Scope
- Industry
- Published
- September 29, 2026
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on natcopharma.co.in
Leave the platform to read the original full article on the publisher site.
Source: Natco Pharma
Scope: Industry
Evidence: Tier 1 · Company source
Related coverage
More related coverage
Chugai Pharmaceutical News/5h ago
中外製薬とInxMed、RAF-MEK分子糊SPYK04に関する全世界におけるライセンス契約を締結
Chugai Pharmaceutical/5h ago
Chugai and InxMed Enter into a Worldwide License Agreement for SPYK04, a RAF-MEK Molecular Glue
Fidson Healthcare/5h ago
Fidson Selected as Regional Sublicensee to Expand Access to Influenza Treatment and Strengthen Pandemic Preparedness
Ipsen/6h ago